Recent studies examine self-management strategies for breast cancer treatment-related cardiotoxicity and highlight risks of vertebral fractures after discontinuing denosumab therapy in patients receiving aromatase inhibitors.
The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration BTK inhibitor regimen for CLL/SLL and cleared monthly dosing for amivantamab in EGFR-mutated NSCLC. Additional regulatory reviews are underway for PCNSL and breast cancer treatments.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07366112 |
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment |
NOT_YET_RECRUITING | PHASE2 |
| NCT07294339 |
A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer |
NOT_YET_RECRUITING | NA |
| NCT07264998 |
Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea |
RECRUITING | |
| NCT07073755 |
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd |
RECRUITING | |
| NCT06970912 |
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer |
RECRUITING | PHASE2 |
| NCT06878248 |
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06805812 |
Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study |
RECRUITING | |
| NCT06570031 |
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06518837 |
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer |
RECRUITING | PHASE2 |
| NCT05868226 |
PRE-I-SPY Phase I/Ib Oncology Platform Program |
RECRUITING | PHASE1 |
